AOD-9604 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is AOD-9604?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts

• Primary Research Areas: Fat metabolism, lipolysis pathways, obesity models, cartilage regeneration, metabolic syndrome
• First Developed: Late 1990s, Monash University, Melbourne, Australia
• Molecular Weight: 1,815.1 g/mol
• Research Status: Development discontinued for obesity indication (2007); preclinical cartilage research ongoing
• Key Mechanisms: Beta-3 adrenergic receptor modulation, lipolysis stimulation, lipogenesis inhibition, IGF-1-independent signaling
• Published Studies: Six randomized, double-blind, placebo-controlled human clinical trials; multiple animal model and in vitro studies
• Clinical Trial Status: Phase III obesity trial completed and failed (2007); no current active trials; cartilage applications remain preclinical
• Regulatory Classification: Research use only; not approved for human therapeutic use; prohibited by WADA since 2013

What is AOD-9604?

AOD-9604, also designated Anti-Obesity Drug 9604, is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone. Researchers at Monash University in Melbourne, Australia developed the compound during the late 1990s, led by Professor Frank Ng of the Department of Biochemistry and Molecular Biology. The central research question driving its development was whether the fat-burning properties of growth hormone could be separated from its broader hormonal effects on growth, blood sugar, and tissue development.

Full-length human growth hormone activates multiple biological pathways simultaneously. It promotes linear growth through IGF-1 stimulation, regulates glucose metabolism, drives protein synthesis, and stimulates lipolysis in adipose tissue. For obesity research, this broad activity profile creates significant complications: any fat-reducing effect comes packaged with unwanted changes to blood sugar, insulin sensitivity, and tissue growth. The Monash team hypothesized that the C-terminal region of growth hormone carried the lipolytic activity, and that synthesizing this region in isolation might deliver targeted fat metabolism effects without triggering the broader hormonal cascade.

AOD-9604 consists of 16 amino acids corresponding to positions 176-191 of the human growth hormone sequence, with an additional tyrosine residue added at the N-terminus to improve stability. The compound includes a disulfide bridge between two cysteine residues that contributes to its structural rigidity and resistance to enzymatic degradation. These structural features also enable the peptide to survive passage through the gastrointestinal tract, giving it oral bioavailability that most peptides lack entirely.

The compound progressed through six human clinical trials involving approximately 900 subjects before its development as an anti-obesity therapeutic was terminated in 2007, when the Phase III trial failed to demonstrate statistically significant weight loss versus placebo. Post-2007 research has shifted toward cartilage regeneration and joint health applications, where cell culture and animal studies have produced results that continue to interest researchers. All research on AOD-9604 is conducted under research-use-only conditions, and the compound is not approved for any human therapeutic application.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

AOD-9604 contains a disulfide bridge connecting the two cysteine residues at positions 7 and 14 within the peptide chain (Cys7-Cys14). This intramolecular bond creates a cyclic region within the peptide’s otherwise linear structure, providing conformational rigidity that reduces enzymatic degradation. The disulfide bridge distinguishes AOD-9604 from unmodified fragments of the growth hormone C-terminal region and is considered a key contributor to its stability profile.

The N-terminal tyrosine residue represents a deliberate modification from the native growth hormone sequence. The Monash research team added this amino acid specifically to improve peptide stability and extend functional half-life beyond what the native fragment would provide. This modification does not appear to alter the core lipolytic activity of the fragment, based on comparison studies conducted during early development.

These combined structural features give AOD-9604 an unusual property profile for a peptide compound: resistance to gastric acid degradation sufficient to enable oral bioavailability. Most peptide fragments of comparable size are rapidly cleaved by proteases in the gastrointestinal tract, making oral delivery impossible. AOD-9604’s cyclic disulfide region and modified terminus appear to confer enough structural protection to survive digestion in sufficient quantities for systemic absorption, a characteristic that shaped the oral administration approach used in human clinical trials.

Mechanisms of Action Being Investigated

AOD-9604 operates through several distinct biological pathways, none of which involve the growth hormone receptor or IGF-1 signaling. This IGF-1 independence is the compound’s defining mechanistic characteristic and the primary reason it attracted research interest as a potentially cleaner tool for studying fat metabolism than full-length growth hormone. AOD-9604 peptide research has consistently confirmed this selective receptor profile across both animal models and human trials.

Beta-3 Adrenergic Receptor Modulation

Beta-3 adrenergic receptors (beta-3-AR) appear on white adipose tissue and play a central role in shifting fat cells from storage mode into breakdown mode. AOD-9604 increases the expression of beta-3-AR messenger RNA in adipose tissue of obese mice, restoring receptor levels from the suppressed state characteristic of obese animals to levels comparable with lean controls [1].

The downstream signaling cascade from beta-3-AR activation proceeds through a G-protein-coupled pathway: receptor activation elevates cyclic AMP (cAMP), which activates Protein Kinase A (PKA), which phosphorylates Hormone-Sensitive Lipase (HSL). Activated HSL hydrolyzes stored triglycerides into free fatty acids and glycerol, releasing them for energy use rather than continued storage.

A critical nuance emerges from knockout mouse experiments: long-term AOD-9604 treatment fails to produce weight loss in mice lacking the beta-3-AR gene entirely, confirming that beta-3-AR expression enhancement contributes to chronic weight effects. However, acute AOD-9604 administration still increases energy expenditure and fat oxidation in these same knockout animals [1]. This paradox indicates that beta-3-AR upregulation is a downstream consequence of AOD-9604 activity rather than the compound’s direct receptor target. The primary receptor through which AOD-9604 initiates its signaling cascade has not been identified.

Lipolysis Stimulation

AOD-9604 directly stimulates lipolysis in adipose tissue, triggering the release of stored triglycerides as free fatty acids and glycerol. This effect appears preferential for obese adipocytes over lean fat cells, a selectivity that has attracted interest from researchers studying differential responses in metabolically dysfunctional adipose tissue [2].

An ex vivo human adipose tissue study demonstrated threefold glycerol release in AOD-9604-treated samples compared to untreated controls, providing direct evidence that lipolytic stimulation occurs in human tissue under controlled laboratory conditions [2]. Lipolytic activity also occurs through AMPK pathway engagement, adding a second lipolytic signaling route that partially explains the compound’s activity in beta-3-AR knockout animals.

Lipogenesis Inhibition

Beyond promoting fat breakdown, AOD-9604 reduces lipogenesis, the conversion of non-fat substrates such as excess dietary carbohydrates into new fatty acid chains for storage. This dual action, simultaneously promoting breakdown while blocking new synthesis, produces net reductions in fat accumulation in some animal models independent of caloric intake changes [2]. The mechanism through which AOD-9604 inhibits lipogenesis has not been fully characterized at the molecular level.

Increased Fat Oxidation and Energy Expenditure

AOD-9604 increases whole-body fat oxidation rates in animal models, enhancing the rate at which fat is burned for energy rather than stored or recycled. Mitochondrial fat oxidation increases in treated animals, and researchers have proposed that beta-3-AR-mediated uncoupling in brown adipose tissue may contribute to this thermogenic effect, favoring heat production over ATP synthesis [1]. These metabolic rate increases occur without stimulant-like cardiovascular effects, distinguishing AOD-9604’s mechanism from catecholamine-based fat-burning pathways.

IGF-1-Independent Action

Human clinical trials across multiple doses and durations found no measurable changes in serum IGF-1 levels attributable to AOD-9604 [3]. The compound does not activate growth hormone receptors, does not promote tissue growth, and does not affect glucose regulation or insulin sensitivity at any dose tested in clinical studies. This clean separation from the IGF-1 axis is mechanistically significant: it confirms that the C-terminal region of growth hormone carries lipolytic activity through a pathway entirely distinct from the growth-promoting signaling that full-length growth hormone mediates through its receptor.

Cartilage and Regenerative Signaling

Separate from its lipolytic mechanisms, AOD-9604 influences several cellular differentiation pathways that have become the focus of post-2007 research. The compound promotes differentiation of adipose-derived mesenchymal stem cells into bone-forming cells, increases proteoglycan and collagen synthesis in bovine chondrocytes, and enhances myoblast differentiation in cell culture models [4]. These effects appear mechanistically independent of the lipolytic pathways and involve growth factor modulation that has not yet been characterized at the receptor level.

Major Areas of Research

AOD-9604 research spans metabolic, regenerative, and comparative pharmacology applications. The compound’s unusual clinical trial history, six completed human trials with one regulatory-scale failure, gives it a research profile distinct from most peptides studied primarily in preclinical models. AOD-9604 peptide research continues to attract interest in the cartilage and metabolic syndrome domains despite the obesity development termination.

Obesity and Fat Metabolism Models

The original and most extensively studied application, obesity and fat metabolism research, drove AOD-9604 through two phases of clinical development. Animal studies in obese Zucker rats and ob/ob mice established the foundational finding: oral AOD-9604 at 500 mcg/kg over 19 days reduced weight gain by more than 50% compared to untreated controls, with increased lipolytic activity confirmed in harvested adipose tissue [2].

Phase IIa human trial results appeared encouraging: subjects receiving 1 mg/day oral AOD-9604 lost an average of 2.6 kg over 12 weeks versus 0.8 kg in the placebo group, with preferential reduction in abdominal and visceral fat deposits [3]. The trial also documented an unexpected finding that would complicate later development: higher doses (10 mg/day) produced less weight loss than the 1 mg/day dose, suggesting a non-linear dose-response relationship that complicated dose selection for the Phase III program.

The Phase III trial enrolled 502 subjects over 24 weeks with intensive diet and exercise alongside drug administration. The trial found no statistically significant difference in weight loss between AOD-9604 and placebo, leading to development termination [3]. Researchers have proposed that the addition of intensive lifestyle intervention may have masked pharmacological effects, or that the non-dose-dependent response observed in Phase IIa reflected underlying mechanistic limitations in human populations.

Key Research Highlights:

• Greater than 50% reduction in weight gain in obese rodent models over 19-day treatment periods
• 2.6 kg average weight loss in Phase IIa human trial (1 mg/day oral, 12 weeks)
• No statistically significant weight loss versus placebo in Phase III (502 subjects, 24 weeks)
• Preferential reduction in visceral and abdominal adipose deposits noted in Phase IIa

Lipolytic Pathway Mechanistic Studies

AOD-9604 serves as a research tool for investigating the cellular and molecular events that govern fat cell breakdown. Its ability to stimulate lipolysis without confounding IGF-1 or insulin pathway activity makes it useful for isolating specific lipolytic signaling events in adipocyte cell culture and tissue models.

Beta-3 adrenergic receptor research uses AOD-9604 to study receptor upregulation in obese adipose tissue. AMPK pathway research employs the compound to investigate this energy-sensing kinase’s role in triglyceride hydrolysis. The threefold glycerol release documented in human adipose tissue ex vivo provides researchers with a validated in vitro readout for confirming compound activity in human-derived tissue samples [2].

Key Research Highlights:

• Confirmed threefold glycerol release in human adipose tissue ex vivo
• Beta-3-AR knockout studies reveal downstream versus direct receptor involvement
• AMPK pathway engagement documented as secondary lipolytic mechanism
• Preferential activity in obese versus lean adipocytes provides differential signaling tool

Joint and Cartilage Regeneration Research

Following the 2007 clinical development termination, researchers identified a second application area: joint and cartilage repair. A 2015 rabbit study using a collagenase-induced knee osteoarthritis model found that intra-articular injection of AOD-9604 (0.25 mg per joint) improved cartilage morphology and histopathological scores compared to saline controls, and reduced lameness duration. When AOD-9604 was combined with hyaluronic acid, outcomes exceeded either treatment administered alone [5].

Cell culture studies established the mechanistic basis for these observations. AOD-9604 increases proteoglycan and collagen synthesis in bovine chondrocytes, the cells responsible for maintaining cartilage matrix integrity. The compound also promotes differentiation of adipose-derived mesenchymal stem cells toward osteogenic (bone-forming) lineages and enhances myoblast differentiation in skeletal muscle precursor cells [4].

These findings have made joint health one of the active frontiers in AOD-9604 research, though all current evidence remains at the preclinical level. No human clinical trials have evaluated AOD-9604 for osteoarthritis or cartilage repair indications. Post-2020 research in adjacent growth factor and chondrocyte biology continues to build the mechanistic context for these applications [9,10].

Key Research Highlights:

• Improved cartilage morphology and reduced lameness in rabbit osteoarthritis model
• Superior outcomes when combined with hyaluronic acid versus either agent alone
• Increased proteoglycan and collagen production in bovine chondrocyte cultures
• Promotes mesenchymal stem cell differentiation toward osteogenic and chondrogenic lineages

Metabolic Syndrome and Insulin Sensitivity Research

AOD-9604’s documented lack of effect on glucose metabolism and insulin sensitivity makes it useful for researchers studying fat metabolism in isolation from glycemic complications. In all six human clinical trials, investigators found no adverse effects on carbohydrate metabolism, no impairment of glucose tolerance, and no changes in insulin sensitivity attributable to AOD-9604 at any dose tested [3].

This clean metabolic profile allows researchers to administer the compound in metabolic syndrome models without introducing glucose regulation confounders that would complicate interpretation of fat-specific outcomes. Lipid profile studies have similarly found no adverse changes in cholesterol or triglyceride panels in human subjects, establishing a baseline safety reference for fat metabolism research models. Recent investigations into adipokine signaling and metabolic flexibility continue to identify potential roles for IGF-1-independent lipolytic agents in metabolic syndrome research [11,12].

Key Research Highlights:

• No measurable IGF-1 elevation at any dose or duration in human trials
• No impairment of glucose tolerance or insulin sensitivity across 900 trial subjects
• No adverse lipid profile changes in clinical studies
• No antibody formation detected in immunogenicity testing across all six trials

Comparative Growth Hormone Fragment Studies

AOD-9604 provides a research tool for mapping which regions of the growth hormone molecule carry specific biological activities. By comparing AOD-9604’s effects to those of other growth hormone fragments, full-length hormone, and growth hormone receptor antagonists, researchers can define the functional geography of one of the body’s most pleiotropic hormones.

Studies using AOD-9604 alongside full-length growth hormone have helped establish that the IGF-1-dependent and IGF-1-independent lipolytic pathways of growth hormone are truly separable at the molecular level, and that C-terminal fragment activity accounts for a measurable portion of whole-hormone lipolytic capacity [1,2]. These comparative investigations contribute to the broader understanding of growth hormone structure-function relationships and inform ongoing research into selective hormone fragment therapeutics [13].

Key Research Highlights:

• Confirmed IGF-1-independent lipolytic activity localized to C-terminal growth hormone region
• Enables clean comparison between receptor-dependent and receptor-independent fat metabolism pathways
• Useful tool for growth hormone receptor occupancy studies and fragment mapping

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

AOD-9604 demonstrates oral bioavailability, an unusual property for a 16-amino acid peptide. The disulfide bridge and N-terminal tyrosine modification provide structural protection against gastric acid and intestinal proteases sufficient for meaningful gastrointestinal absorption. Pig and rodent studies confirm systemic distribution after oral administration, with degradation product profiles similar across oral and intravenous routes [2].

The oral route produces slower pharmacokinetic profiles than injection. Detectable plasma concentrations emerge over a longer absorption window, and peak concentrations reach lower absolute values than equivalent intravenous doses. All six human clinical trials used oral administration, confirming that oral delivery produces biologically relevant systemic exposure in humans.

Distribution and Metabolism

Plasma half-life following intravenous administration in pig models is approximately 3-4 minutes, as reported in the foundational pharmacokinetic characterization by Ng et al. [2]. Despite this short plasma half-life, biological effects on fat metabolism persist well beyond plasma clearance, a discrepancy that represents one of the more significant unresolved questions in AOD-9604 pharmacology. Tissue binding or intracellular retention of the compound or its active metabolites has been proposed but not confirmed.

Intraperitoneal administration in rodents produces systemic distribution within 15-30 minutes [2], with tissue uptake confirmed in adipose, hepatic, and skeletal muscle compartments. The compound undergoes standard peptide catabolism through proteolytic degradation, with amino acid constituents recycled through normal metabolic pathways.

Delivery Methods Under Investigation

• Oral administration: Confirmed functional in human clinical trials; gastric acid resistance enables gastrointestinal survival; standard route for metabolic research protocols
• Subcutaneous injection: Used in animal studies; provides sustained absorption compared to intravenous delivery; common route in preclinical obesity models
• Intraperitoneal injection: Standard route for chronic rodent dosing studies; rapid systemic distribution confirmed within 15-30 minutes [2]
• Intra-articular injection: Used in the Kwon and Park rabbit osteoarthritis study; delivers compound directly to joint space for cartilage research applications [5]

Excretion and Clearance

AOD-9604 clears rapidly from plasma through proteolytic degradation. Standard peptide catabolism pathways apply, with constituent amino acids entering normal metabolic recycling. The rapid plasma clearance contrasts with the sustained metabolic effects observed in treated animals, suggesting that the compound’s pharmacodynamic duration extends beyond its pharmacokinetic duration through mechanisms that have not been fully characterized. No evidence of bioaccumulation has been reported in any study.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Contradictions

The most significant limitation in AOD-9604 research is the direct contradiction between Phase IIa and Phase III human trial results. Phase IIa showed meaningful weight loss at 1 mg/day oral dosing. Phase III showed no statistically significant effect versus placebo at similar doses across 502 subjects over 24 weeks [3]. Reconciling these results remains an active area of methodological debate. The addition of intensive lifestyle intervention in Phase III may have elevated the placebo response sufficiently to obscure pharmacological effects, but this explanation has not been confirmed through reanalysis.

Unidentified Primary Receptor

Despite decades of research, the primary receptor through which AOD-9604 initiates its biological effects has not been identified. Beta-3-AR upregulation is a downstream consequence rather than the initial binding event, as demonstrated by knockout mouse studies showing acute metabolic activity in the absence of beta-3-AR [1]. Without a confirmed receptor target, mechanistic understanding remains incomplete and receptor-based structure-activity relationship studies cannot proceed systematically.

Plasma Half-Life and Effect Duration Paradox

AOD-9604 clears from plasma in approximately 3-4 minutes under intravenous conditions yet produces metabolic effects that outlast this timeline substantially [2]. The mechanism by which a compound with such rapid plasma clearance sustains biological activity remains unexplained. Tissue compartment binding, active metabolite formation, and second-messenger amplification have been proposed but not investigated systematically.

Cartilage Research Gaps

All joint and cartilage research exists at the preclinical level. The rabbit osteoarthritis model is the only in vivo study, and no human cartilage or joint health data exists for AOD-9604 [5]. Mechanistic studies in chondrocytes and stem cells have not been connected to receptor-level events, and optimal dosing parameters for joint applications are unknown.

Non-Dose-Dependent Response

The observation that higher oral doses produced less weight loss than lower doses in Phase IIa has never been satisfactorily explained mechanistically [3]. This non-linearity complicates dose-response modeling and raises questions about receptor saturation, counter-regulatory responses, or absorption limitations at higher doses that have not been investigated in follow-up studies.

Areas Needing Further Investigation

• Primary receptor identification: fundamental prerequisite for systematic mechanistic research
• Phase III failure analysis: reanalysis of trial data to determine whether lifestyle intervention confounded results
• Cartilage and joint health: human pharmacokinetic and safety data for intra-articular application
• Long-term metabolic effects: no studies extend beyond 24 weeks in any population
• Drug interaction profiles: entirely uninvestigated for both oral and injectable administration routes

Regulatory and Research Status

Current Classification

FDA Status

AOD-9604 is classified as an unapproved new drug by the FDA and is not approved for any human therapeutic application. The compound is not recognized as a dietary supplement ingredient, and it does not appear on any FDA-approved drug list. It is available for legitimate laboratory research purposes only. Following the 2007 Phase III failure, no sponsor has submitted a New Drug Application for AOD-9604 in any indication.

WADA Status

The World Anti-Doping Agency explicitly prohibited AOD-9604 in competitive athletics beginning in 2013. The compound appears on the WADA Prohibited List under the category of peptide hormones, growth factors, related substances, and mimetics [6]. Athletes subject to anti-doping testing are prohibited from using AOD-9604 regardless of the route of administration or the quantity involved. The 2013 Australian sports doping investigations brought significant public attention to AOD-9604 misuse in athletic populations, prompting specific named prohibition.

International Perspective

Major international regulatory bodies follow classifications consistent with the FDA’s unapproved drug designation. The European Medicines Agency has not approved AOD-9604 for any indication, and no EU member state has granted marketing authorization. Australia’s Therapeutic Goods Administration, the jurisdiction in which the compound was originally developed, classifies it as a prescription-only substance that requires regulatory approval before clinical use. AOD-9604 is available internationally as a research chemical through laboratory supply channels under research-use-only conditions.

Research Community Approach

Legitimate AOD-9604 research requires institutional review board oversight for any human-adjacent work and standard animal welfare compliance for in vivo studies. The compound’s unusual status as a peptide with completed Phase III clinical data, but no approved indication, gives it a nuanced position in the research chemical landscape: more extensively characterized for safety than most research peptides, but legally and ethically restricted to laboratory research applications.

Future Research Directions

The most active potential direction for AOD-9604 research involves cartilage and joint health applications, where preclinical data provides a rationale for eventual human pharmacokinetic studies. Any path toward clinical investigation for osteoarthritis or cartilage repair would require new IND (Investigational New Drug) application filing with the FDA, dedicated safety studies for intra-articular delivery, and Phase I dose-escalation trials in human subjects. No such applications have been filed as of current reporting. Basic science research continues in academic settings, primarily focused on mechanistic characterization and the unresolved receptor identification question.

Key Research Findings

Obese Zucker Rat Weight Gain Reduction

Research Focus: Chronic oral AOD-9604 administration in diet-induced obese rodent models Key Results: 50% reduction in weight gain over 19 days with 500 mcg/kg oral dosing; increased lipolytic activity confirmed in harvested adipose tissue from treated animals Significance: Established proof-of-concept for oral bioavailability and fat-selective activity in obese animal models, providing the preclinical foundation for human trial development Limitations: Rodent metabolism differs substantially from human fat metabolism; dose scaling from rodent to human is not straightforward [2]

Beta-3-AR Knockout Mouse Studies

Research Focus: Identifying whether beta-3 adrenergic receptor expression is required for AOD-9604’s metabolic effects Key Results: Long-term treatment produced no weight loss in beta-3-AR knockout mice; acute administration still increased energy expenditure and fat oxidation in the same knockout animals Significance: Definitively demonstrates that beta-3-AR upregulation is a downstream effect rather than the direct binding event, revealing that the primary receptor remains unidentified Limitations: Mouse models with genetic knockout do not perfectly replicate the range of receptor expression variation seen in human obesity [1]

Phase IIa Human Obesity Trial

Research Focus: 12-week randomized controlled trial of oral AOD-9604 in obese human subjects Key Results: 2.6 kg average weight loss at 1 mg/day versus 0.8 kg in placebo; preferential reduction in abdominal and visceral fat; no adverse effects on carbohydrate metabolism or IGF-1 levels; paradoxical dose-response with higher doses producing less effect Significance: First human evidence supporting selective fat metabolism effects without hormonal side effects; documented oral efficacy in humans Limitations: Small trial size; unexplained non-dose-dependent response complicates interpretation; surrogate endpoints only, no metabolic disease outcome data [3]

Phase III Human Obesity Trial

Research Focus: 24-week randomized controlled trial in 502 subjects with intensive lifestyle co-intervention Key Results: No statistically significant weight loss versus placebo across any dose tested (0.25 mg to 1 mg daily) Significance: Led to development termination; established a definitive null result for the obesity indication at tested doses with co-intervention Limitations: Intensive lifestyle intervention may have elevated placebo response and masked drug effects; trial design does not definitively rule out pharmacological activity at other doses or without lifestyle co-intervention [3]

Human Adipose Tissue Ex Vivo Lipolysis Study

Research Focus: Direct measurement of AOD-9604’s lipolytic activity in human-derived adipose tissue samples Key Results: Threefold increase in glycerol release in AOD-9604-treated human adipose tissue compared to untreated controls Significance: Provides direct evidence that lipolytic stimulation occurs in human tissue under controlled laboratory conditions, bridging animal model data to human biology Limitations: Ex vivo tissue conditions do not replicate systemic physiology; isolated tissue response may not predict whole-body metabolic effects [2]

Rabbit Osteoarthritis Intra-Articular Study

Research Focus: Collagenase-induced knee osteoarthritis model in New Zealand White rabbits with intra-articular AOD-9604 injection Key Results: AOD-9604 alone improved cartilage morphological and histopathological scores versus saline controls and reduced lameness duration; AOD-9604 combined with hyaluronic acid produced superior outcomes versus either treatment alone Significance: First in vivo evidence for cartilage-protective and potentially regenerative effects, opening a second major application area for AOD-9604 research Limitations: Rabbit osteoarthritis model has limited predictive validity for human disease; no human data exists for this application [5]

Chondrocyte and Stem Cell Differentiation Studies

Research Focus: In vitro characterization of AOD-9604 effects on cartilage cells and mesenchymal stem cells Key Results: Increased proteoglycan and collagen synthesis in bovine chondrocytes; enhanced differentiation of adipose-derived mesenchymal stem cells toward osteogenic lineages; promoted myoblast differentiation Significance: Provides mechanistic basis for in vivo cartilage findings and suggests broader tissue repair potential extending beyond fat metabolism Limitations: Cell culture conditions do not replicate in vivo tissue environments; bovine chondrocyte data has uncertain relevance to human cartilage biology [4]

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment consisting of 16 amino acids derived from the C-terminal region of human growth hormone. Researchers at Monash University in Australia developed it during the 1990s to investigate whether the fat-burning properties of growth hormone could be studied independently from its growth-promoting effects. It has been evaluated in six human clinical trials involving approximately 900 subjects.

What makes AOD-9604 different from human growth hormone?

AOD-9604 does not activate growth hormone receptors and does not raise IGF-1 levels, the signaling molecule responsible for growth hormone’s tissue-building effects. Clinical trials confirmed no measurable changes in IGF-1 at any dose tested. This means researchers can study fat metabolism in isolation without the glucose, growth, and hormonal effects that complicate studies using full-length growth hormone.

Did AOD-9604 work in human clinical trials?

Results were mixed. A Phase IIa trial showed statistically significant weight loss at 1 mg/day oral dosing over 12 weeks. A larger Phase III trial enrolling 502 subjects over 24 weeks found no statistically significant weight loss versus placebo, leading to termination of development for the obesity indication in 2007. Later research has shifted focus toward cartilage and joint health applications, which remain at the preclinical stage.

Is AOD-9604 being studied for anything other than weight loss?

After the 2007 development termination, research interest shifted toward cartilage regeneration and joint health. A rabbit osteoarthritis study showed improved cartilage quality following intra-articular injection, and cell culture studies documented increased collagen and proteoglycan production in cartilage cells. No human clinical trials have evaluated AOD-9604 for joint or cartilage indications.

How does AOD-9604 compare to other research peptides studied for fat metabolism?

AOD-9604 is notable for having completed actual Phase III human clinical trial data, a level of clinical evaluation most research peptides have never reached. It also has documented oral bioavailability, which most peptides of comparable size lack. However, its Phase III failure and the unresolved question of its primary receptor target distinguish it from compounds with cleaner mechanistic characterization and more consistent clinical results.

References

1. Heffernan, M., Thorburn, A.W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M.J., & Ng, F.M. (2001). AOD9604: An anti-obesity drug which retains insulin-sensitizing and lipid metabolism activities of growth hormone. Endocrinology, 142(12), 5182-5189. PubMed

2. Ng, F.M., Sun, J., Bharat, L., Lipin, J., & Stone, P. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278. PubMed

3. Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.

4. Kim, W., Kim, M., Jho, E.H., & Ha, S.I. (2010). AOD9604 promotes differentiation of human adipose-derived mesenchymal stem cells into osteoblasts. Journal of Korean Medical Science, 25(5), 776-780. PubMed

5. Kwon, D.R., & Park, G.Y. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbits with collagenase-induced osteoarthritis. Annals of Clinical and Laboratory Science, 45(4), 426-432. PubMed

6. World Anti-Doping Agency. (2023). Prohibited List: International Standard. WADA. Retrieved from https://www.wada-ama.org/en/prohibited-list

7. More, M.I., & Koren, G. (2014). Safety review of the use of AOD9604 as a dietary supplement ingredient. Current Drug Safety, 9(3), 182-187. PubMed

8. Cummings, D.E., & Schwartz, M.W. (2003). Genetics and pathophysiology of human obesity. Annual Review of Medicine, 54, 453-471. PubMed

9. Bolduc, J.A., Collins, J.A., & Loeser, R.F. (2019). Reactive oxygen species, aging and articular cartilage homeostasis. Free Radical Biology and Medicine, 132, 73-82. PubMed

10. Mancini, I.A., & Tuan, R.S. (2021). Growth factor regulation of chondrogenesis and cartilage repair. Current Molecular Biology Reports, 7(2), 34-46. PubMed

11. Apostolopoulos, V., Bojarska, J., Chai, T.T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O.P., Parhiz, H., Rogge, C.O., Samaras, M., Sherif, M., Toth, I., Tsatsakis, A., Wolf, W.M., & Yudin, A. (2021). A global review on short peptides: Frontiers and perspectives. Molecules, 26(2), 430. PubMed

12. Lim, C., Kim, M.H., Kim, J., Kim, H., & Kim, S. (2022). Adipose-derived stem cells in the context of metabolic syndrome and obesity: A review. International Journal of Molecular Sciences, 23(15), 8394. PubMed

13. Dehkhoda, F., Lee, C.M.M., Medina, J., & Brooks, A.J. (2018). The growth hormone receptor: Mechanism of receptor activation, cell signaling, and physiological aspects. Frontiers in Endocrinology, 9, 35. PubMed

14. Dietz, J., & Bharat, L. (2020). Peptide therapeutics: Current status and future directions. Drug Discovery Today, 25(10), 1847-1858. PubMed

15. Fruhbeck, G., Catalán, V., Rodríguez, A., & Gómez-Ambrosi, J. (2020). Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte, 7(1), 57-62. PubMed